A: Triamcinolone acetonide for Vitiligo

Phase-Based Progress Estimates
VitiligoTriamcinolone Acetonide - Drug
All Sexes
What conditions do you have?

Study Summary

Vitiligo is a chronic acquired disease characterized by well defined white macules and patches affecting the skin. It has a major psychosocial impact on affected patients. There are many treatment modalities available for vitiligo, however, none of them cure the disease. Topical corticosteroids (CS) are the most effective monotherapy for localized vitiligo. Treatment with intralesional corticosteroids (ILCS) is commonly used in many dermatologic conditions. However, there are only a few studies published on the use of ILCS in vitiligo. This is a prospective double-blind randomized clinical trial to assess efficacy and safety of ILCS in the treatment of vitiligo. Four treatment sessions will be done over 4 to 6 months. The investigators will compare intralesional triamcinolone acetonide (active treatment) to normal saline (placebo).

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 3-5 weeks after each treatment session

Week 5
Assessment of side effects in each half including atrophy, telangiectasia, hyperpigmentation and hypopigmentation using a severity scale as follows: 0=none, 1=mild, 2=moderate, 3=severe.
Assessment of the degree of repigmentation based on the modified VASI score for each half. We will consider the treatment successful if there was ≥50% change in modified VASI score from baseline.

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

A: Triamcinolone acetonide
1 of 2
B: Normal saline
1 of 2

Active Control

Non-Treatment Group

18 Total Participants · 2 Treatment Groups

Primary Treatment: A: Triamcinolone acetonide · No Placebo Group · Phase 2

B: Normal salinePlaceboComparator Group · 1 Intervention: B: Normal saline · Intervention Types:
A: Triamcinolone acetonide
ActiveComparator Group · 1 Intervention: Triamcinolone Acetonide · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3-5 weeks after each treatment session

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,325 Previous Clinical Trials
1,534,075 Total Patients Enrolled
4 Trials studying Vitiligo
107 Patients Enrolled for Vitiligo
Harvey Lui, MD, FRCPCPrincipal InvestigatorUniversity of British Columbia
3 Previous Clinical Trials
62 Total Patients Enrolled
3 Trials studying Vitiligo
62 Patients Enrolled for Vitiligo

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: